Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Can-Fite BioPharma ( (CANF) ) just unveiled an update.
On February 17, 2026, Can-Fite BioPharma reported a peer-reviewed publication in the International Journal of Obesity showing that its lead drug namodenoson has a significant anti‑obesity effect in preclinical models. The study found that namodenoson reduced adipocyte proliferation and lipid accumulation in vitro and curtailed weight gain in a high‑fat diet mouse model, aligning with earlier Phase IIa data in MASH patients showing reductions in liver fat and body weight.
Researchers also detailed a multi‑pathway mechanism in which namodenoson increased adiponectin and suppressed PI3K, NF‑κB, Akt and Wnt/β‑catenin signaling, underpinning its metabolic impact. With namodenoson already in advanced trials for liver cancer and MASH and backed by a broad patent estate and favorable safety record, the findings broaden its potential into the rapidly expanding obesity treatment market, which is projected to reach $60.5 billion by 2030.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs for cancer, liver and inflammatory diseases, targeting multi‑billion‑dollar markets. Its lead candidates include piclidenoson for psoriasis and namodenoson for hepatocellular carcinoma, MASH and pancreatic cancer, alongside CF602 for erectile dysfunction, all of which have shown an excellent safety profile in more than 1,600 patients to date.
Average Trading Volume: 539,265
Technical Sentiment Signal: Sell
Current Market Cap: $5.67M
For a thorough assessment of CANF stock, go to TipRanks’ Stock Analysis page.